|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-5-13
|
|
pubmed:abstractText |
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Terutroban is a selective TP receptor antagonist, i.e. a specific antagonist of the thromboxane A(2) and prostaglandin endoperoxide receptors, shown to improve endothelial function after a single administration in patients with coronary artery disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1365-2125
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
844-51
|
|
pubmed:meshHeading |
pubmed-meshheading:21564160-Adult,
pubmed-meshheading:21564160-Aged,
pubmed-meshheading:21564160-Aged, 80 and over,
pubmed-meshheading:21564160-Atherosclerosis,
pubmed-meshheading:21564160-Coronary Artery Disease,
pubmed-meshheading:21564160-Dose-Response Relationship, Drug,
pubmed-meshheading:21564160-Double-Blind Method,
pubmed-meshheading:21564160-Endothelium, Vascular,
pubmed-meshheading:21564160-Female,
pubmed-meshheading:21564160-Humans,
pubmed-meshheading:21564160-Male,
pubmed-meshheading:21564160-Middle Aged,
pubmed-meshheading:21564160-Naphthalenes,
pubmed-meshheading:21564160-Platelet Aggregation,
pubmed-meshheading:21564160-Propionic Acids,
pubmed-meshheading:21564160-Receptors, Thromboxane,
pubmed-meshheading:21564160-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.
|
|
pubmed:affiliation |
INSERM, Unité 955, Université Paris-Est Créteil Val de Marne, Faculté de Médecine, UMR U955, France.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
